To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
A Multicenter, Randomized, Double-blind, Placebo -Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
In the register
The register attaches this trial to GT20029 (Kintor Pharmaceutical), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Participants (registry)
- 180
- Start
- April 2023
- Primary completion
- December 2023
- Study completion
- June 2024
- Last registry update
- November 2024
- Countries
- China
Conditions studied: Alopecia, Male Pattern Hair Loss
Interventions: GT20029 Tincture, GT20029 matching placebo
Other trials of GT20029
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.